Proteogenomics for the Study of Gastrointestinal Stromal Tumors.
Proteogenomics for the Study of Gastrointestinal Stromal Tumors.
复制标题
用于胃肠道间质肿瘤研究的蛋白质基因组学。
DOI：
10.1007/978-3-319-42316-6_9
复制
发表时间：
2016
期刊：
影响因子：
--
通讯作者：
Kondo T.
中科院分区：
文献类型：
--
作者：
Yamasaki H;Miyamoto M;Yamamoto Y;Kondo T;Watanabe T;Ohta T.;Ikemoto-Uezumi M.;Kondo T.
胃肠道间质瘤（GIST）是胃肠道最常见的间叶性肿瘤。KIT或血小板衍生生长因子受体α（PDGFRA）的功能获得性突变驱动大多数GIST，85%的GIST还包含两种受体酪氨酸激酶之一的致癌突变。酪氨酸激酶抑制剂的出现对GIST的临床实践产生了重大影响。然而，超过80%的GIST患者的肿瘤对酪氨酸激酶抑制剂治疗产生耐药性;因此，已经探索了继发性耐药的驱动机制以及用于早期检测复发的生物标志物，以获得更好的临床结局。蛋白质组学是一种多功能和直接的方法，可以找到恶性肿瘤的分子基础以及临床应用的创新种子。GIST中已经获得了全面的基因组、表观基因组和转录组数据，并且蛋白质组数据在多组学研究中具有独特的附加价值。在GIST中使用蛋白质组学方法检查了各种类型的样品，表明蛋白质组学方法具有良好的实用性。
Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the gastrointestinal tract. Gain-of-function mutations inKITor platelet-derived growth factor receptor alpha (PDGFRA) drive most GISTs, and 85 % of GISTs also contain oncogenic mutations in one of two receptor tyrosine kinases. The advent of tyrosine kinase inhibitors has had a significant impact on the clinical practices for GISTs. However, tumors in more than 80 % of GIST patients acquire resistance against treatments with tyrosine kinase inhibitors; thus, driver mechanisms of secondary resistance as well as biomarkers for early detection of recurrence have been explored for better clinical outcomes. Proteomics is a versatile and straightforward approach to finding the molecular basis of malignancies as well as the innovative seeds for clinical applications. Comprehensive genome, epigenome, and transcriptome data have already been obtained and examined together in GISTs, and proteome data has a unique additional value in multi-omics studies. Various types of samples were examined using proteomics modalities in GIST, suggest the promising utility of proteomic approaches.